Molecular Partners Aktie
| 3,35CHF | -0,43CHF | -11,27% |
WKN DE: A12DEH / ISIN: CH0256379097
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 177 | 191 | 182 | 174 | 149 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,06 | 0,99 | 0,04 | 0,03 | 0,00 |
Bilanz (in Mio. CHF) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 164 | 255 | 192 | 154 | 97 |
| Summe Anlagevermögen | 8 | 8 | 6 | 4 | 5 |
| Summe Aktiva | 173 | 262 | 198 | 159 | 102 |
Bilanz (in Mio. CHF) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 65 | 27 | 22 | 17 | 22 |
| Summe Eigenkapital | 107 | 235 | 176 | 142 | 80 |
| Summe Passiva | 173 | 262 | 198 | 159 | 102 |
Adresse
| Wagistrasse 14, 8952 Schlieren | |
| Telefon | +41 (44) 755-77-00 |
| Internet | http://www.molecularpartners.com |
Management
|
Agnete Brunsvik Fredriksen
Independent Director |
|
Alexander Zürcher
Chief Operating Officer |
|
Daniel Steiner
Senior Vice President-Research & Technology |
|
Dominik Höchli
Independent Director |
|
Martin Steegmaier
Chief Scientific Officer |
|
Michael J. Vasconcelles
Independent Non-Executive Director |
|
Michael Pitzner
SVP-Legal, General Counsel & Compliance Officer |
|
Michael Tobias Stumpp
Executive Vice President-Projects |
|
Patrick Amstutz
Chief Executive Officer & Director |
|
Philippe Legenne
Chief Medical Officer |
|
Renate Gloggner
Executive Vice President-People & Community |
|
Robert Hendriks
Senior Vice President-Finance |
|
Sandipkumar S. Kapadia
Independent Director |
|
Seth D. Lewis
SVP-Investor Relations, Communications & Strategy |
|
Steven H. Holtzman
Independent Non-Executive Director |
|
Vito J Palombella
Independent Director |
|
William Matt Burns
Chairman |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.